Veracyte Inc (VCYT)

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.June 1, 2026 7:30 AM
Business Wire Genomic test using whole-transcriptome next-generation sequencing technology will be available to order on June 8 The Prosigna test predicts chemotherapy benefit and quantifies 10-year risk of recurrence to help personalize treatment decisions in patients with early-stage breast cancer On the heels of the landmark OPTIMA trial readout presented at the ASCO Annual Meeting, Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced the U.S. commercial launch of the Prosigna® Breast Risk of Recurrence (ROR) test, a genomic test for patients diagnosed with early-stage hormone-receptor positive (HR+) breast cancer. The Prosigna test determines a patient’s ROR score and estimates the 10-year probability of distant recurrence, providing prognostic insight into how a patient’s cancer may behave over time. These insights also help guide treatment decisions, including predicting whether high risk patients are likely to benefit from chemotherapy or may safely achieve optimal outcomes with endocrine therapy alone, enabling clinicians to make personalized care plans for their patients. The Prosigna test will be available to order starting June 8, 2026. “Every patient diagnosed with breast cancer deserves answers they can trust about what their cancer means and what comes next,” said John Leite, PhD, chief commercial officer, Veracyte?. “Prosigna gives patients and their oncologists a deeper understanding of their individual risk of recurrence, and, for many, whether chemotherapy will truly benefit them or whether they can safely avoid it. That kind of personalized insight can bring greater confidence and reassurance as patients navigate decisions that will shape their care and future health.” In the U.S., more than 225,000 new HR+/HER2- breast cancer cases are diagnosed each year. When breast cancer is diagnosed early and treated appropriately, five-year survival rates reach 92%.1 It is critically important to accurately determine a patient’s risk of recurrence because the effects of treatment escalation or de-escalation have a lasting impact on a patient’s life. Introducing the Prosigna Test: Prediction that adds up The Prosigna test is the only breast cancer test that factors a patient's biological, clinical, and pathological information into a single comprehensive analysis. The test uniquely combines intrinsic subtypes and proliferation score with clinical factors to determine a patient's ROR score and predict the 10-year probability of distant recurrence. This long-term risk assessment provides clinically meaningful insight beyond initial diagnosis, particularly in early-stage breast cancer where recurrence can occur many years later. For decades, clinical risk factors have been a key factor in treatment decisions. Currently, for many patients with high-risk breast cancer who are premenopausal and node positive, standard of care is still chemotherapy and endocrine therapy. New data from the OPTIMA trial shows that nodal involvement and other clinical risk factors do not automatically equate to high risk of recurrence -- for the first time, more than two-thirds of node-positive patients who previously might have received chemotherapy can now safely avoid it based on the Prosigna test results. Why the Prosigna test stands apart: Comprehensive molecular analysis: The Prosigna test was developed from the PAM50 genomic classifier, a foundation for understanding breast cancer biology, which classifies a patient’s individual tumor into one of the four intrinsic subtypes. The Prosigna test is the only test that combines intrinsic subtypes and proliferation score with clinical pathological factors to provide a comprehensive 10-year probability of distant recurrence. Proven across high-risk populations: The Prosigna test is the only test proven to be predictive for chemotherapy benefit decisions in a phase III prospective trial for premenopausal and postmenopausal women with high-risk breast cancer, including those with extensive nodal involvement (up to 9 positive nodes). Superior prognostic accuracy: Extensively validated clinical evidence demonstrates that the Prosigna test is more prognostically accurate than other genomic assays, particularly in the critical 5-10 year breast cancer recurrence window.2, 3 "The PAM50 signature was designed to unlock the clinical utility of modern biological insights into the nature of breast cancer. Through the Prosigna test, these biological insights are now directly informing treatment decisions for patients,” said Matthew Ellis, M.D., Ph.D., one of the developers of the PAM50-based Prosigna test. “The OPTIMA results reinforces the need to ground critical decisions upon tumor biology because understanding risk of recurrence and chemotherapy benefit as distinct principles produces safer and more personalized care.” "Patients diagnosed with early-stage breast cancer deserve access to the most advanced testing available, with the most up to date evidence, so they can make informed treatment decisions with their medical oncology team,” said Jean Sachs, MSS, MLSP Chief Executive Officer of Living Beyond Breast Cancer. “Prosigna's ability to accurately predict risk of recurrence means patients may have the option to avoid chemotherapy and its significant side effects or confidently pursue more aggressive treatment when it will truly benefit them. That is what we want for everyone diagnosed with breast cancer – a personalized treatment plan that is informed by the most up-to-date data." Veracyte is committed to making the Prosigna test accessible to all eligible breast cancer patients. The test is currently covered by most commercial payers, and patients may qualify for financial assistance or a tailored payment plan supported by the Veracyte Access Program for eligible uninsured and underinsured patients. The Prosigna test will be available for ordering starting June 8, 2026 through Veracyte's network nationwide via the easy-to-use Veracyte Ordering Portal. For ordering information and clinical resources, visit www.veracyte.com/prosigna. Veracyte Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter). Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements regarding the potential clinical utility, impact, and benefits of Veracyte’s Prosigna® Breast Risk of Recurrence (ROR) test; the ability of the Prosigna Breast Test to guide adjuvant chemotherapy decisions in early-stage hormone-receptor positive (HR+) patients, including identifying patients who may safely avoid chemotherapy and its side effects without compromising outcomes; the extent to which the results of the OPTIMA trial may influence clinical decision-making; the potential for molecular testing to inform treatment decisions based on tumor biology; and the adoption, use and availability of the Prosigna test and the availability of payer coverage, financial assistance programs, and patient access to the Prosigna test. Forward-looking statements can be identified by words such as “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed,” “ultimately,” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties that could cause actual results to differ materially from our predictions. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 26, 2026, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or the reasons why actual results might differ, whether as a result of new information, future events, or otherwise. References: National Breast Cancer Foundation, Inc., Breast Cancer Facts & Stats; Last updated Apr 20, 2026. https://www.nationalbreastcancer.org/breast-cancer-facts/#mortality. Dowsett M, et al. J Clin Oncol. 2013;31(22):2783-2790. Sestak et. al., JNCI (2013);105(19).   View source version on businesswire.com: https://www.businesswire.com/news/home/20260601512881/en/ Investors:
Kelly Gura
investors@veracyte.com Media:
Molly Cornbleet

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate CancerMay 30, 2026 8:00 AM
Business Wire Study provides first Level 1B evidence for genomic-guided decisions on triplet therapy in advanced disease Additional ASCO data reinforce Decipher Prostate’s utility in high-risk localized disease Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the Decipher Prostate test identifies which men with metastatic prostate cancer benefit from adding the chemotherapy docetaxel to standard hormonal therapy (ADT plus enzalutamide), known as triplet therapy, and who can safely avoid it, providing the first Level 1B 1 evidence for a genomic test guiding this decision. Complementary data presented at the meeting also reinforce Decipher Prostate's clinical utility in high-risk localized disease. Approximately 334,000 men are diagnosed with prostate cancer annually in the United States, including about 30,000 who present with metastatic disease at diagnosis.2, 3 While recent treatment advances have improved outcomes, clinicians still lack precision tools to guide chemotherapy decisions in this setting. “For the first time, the ENZAMET trial analysis shows that a genomic test can guide the decision to add chemotherapy to standard of care hormonal therapy in metastatic prostate cancer," said Prof. Christopher Sweeney, M.B.B.S., DHS., Lead Investigator, South Australian Immunogenomics Cancer Institute, Adelaide University. "Decipher Prostate identifies which patients benefit from treatment intensification, and which can be safely spared chemotherapy, giving clinicians an actionable, evidence-based answer.” The ENZAMET findings build on prior validation in the STAMPEDE and CHAARTED trials, where Decipher Prostate identified patients most likely to benefit from adding docetaxel to ADT alone. ENZAMET advances that evidence with the first demonstration that the test predicts chemotherapy benefit when added to doublet therapy (ADT plus an ARPI). Metastatic Disease: Identifying Which Men Benefit from Chemotherapy The ENZAMET trial is an international, randomized Phase III study conducted by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Researchers performed a pre-specified biomarker analysis using the Decipher Prostate test in 634 patients to assess whether the test could predict benefit from adding chemotherapy to standard hormonal therapy with a median follow-up of 5.6 years. Results showed: Improved outcomes guided by Decipher Prostate: Patients with higher Decipher scores (>0.85) and high-volume disease who received triplet therapy had clinically meaningful better survival compared to those on standard hormonal therapy alone. Patients can be spared from chemotherapy: Patients with lower Decipher scores showed no benefit from adding chemotherapy, suggesting it may be safely avoided. Practice-changing evidence: The treatment-by-biomarker interaction was statistically significant (p=0.043), providing Level 1B evidence for the test's predictive value. Overcoming aggressive disease: Patients with higher Decipher scores who received triplet therapy had more aggressive disease features, yet achieved comparable survival to lower-risk patients on doublet therapy, suggesting chemotherapy offset the poor prognostic effects of aggressive disease biology. Localized Disease: Identifying Which High-Risk Patients Need Treatment Intensification Complementing the ENZAMET findings, a combined analysis of four mature NRG/RTOG trials presented at ASCO 2026 adds to Decipher Prostate's growing body of evidence into high-risk localized prostate cancer. Key findings include: Improved prognostic accuracy: Decipher Prostate significantly improved prognostic accuracy for survival outcomes compared to clinical variables alone. Refined risk classification: Combining NCCN clinical risk classification with Decipher Prostate reclassified approximately 1 in 4 patients. Expanded population for treatment intensification: Results also show many more clinically high-risk patients may benefit from intensification with ARPI. "Decipher Prostate is the most validated transcriptomic test across the full prostate cancer continuum – from active surveillance through metastatic disease," said Elai Davicioni, Ph.D., Veracyte’s Medical Director, Urology. "For clinicians, that means a clearer answer at every decision point. For patients, it means greater confidence that their treatment is guided by the biology of their disease, and not guesswork." About Veracyte Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter). About ANZUP ANZUP is the leading cancer-cooperative clinical trials group that brings together all of the professional disciplines and groups involved in researching and treating urogenital cancers and conduct high quality cancer research. ANZUP’s mission is to improve the lives of people affected by bladder, kidney, testicular, penile and prostate cancers towards our vision of living life without fear of cancer. ANZUP identifies gaps in evidence and areas of clinical need, collaborates with the best clinicians and researchers in genitourinary cancer and communicates frequently and effectively with the broader community along the way. ANZUP receives valuable infrastructure support from the Australian Government through Cancer Australia. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to statements regarding the potential clinical utility and benefits of Veracyte’s Decipher Prostate Test; the ability of Decipher Prostate to identify patients with metastatic prostate cancer who may benefit from treatment intensification, and those who may safely avoid such treatment; the extent to which results from the ENZAMET trial and other studies may influence clinical decision-making; the predictive and prognostic performance of Decipher Prostate across the prostate cancer continuum; and the adoption and use of Decipher Prostate in clinical practice. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed,” "ultimately," and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 26, 2026, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise. References: Simon, R. M., Paik, S. & Hayes, D. F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101, 1446–1452 (2009). https://doi.org/10.1093/jnci/djp335 https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html https://www.cdc.gov/united-states-cancer-statistics/publications/prostate-cancer.html   View source version on businesswire.com: https://www.businesswire.com/news/home/20260530183615/en/ Investors:
Kelly Gura
investors@veracyte.com Media:
Molly Cornbleet

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid ChemotherapyMay 29, 2026 3:15 PM
Business Wire Highest level of prospective evidence supports test-directed chemotherapy decisions in broadest high-risk population to-date, including premenopausal women and patients with extensive lymph node involvement Study shows for the first time, based on the Prosigna test results, that more than two-thirds of patients could be spared chemotherapy without compromising outcomes Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today results from the independent OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) trial, led by University College London (UCL). The results, which will be presented at the ASCO Annual Meeting, conclude that the Prosigna® Breast Risk of Recurrence (ROR) test safely guides adjuvant chemotherapy decisions in patients with early-stage, ER-positive HER2-negative breast cancer. "Behind every breast cancer treatment decision is a patient asking, 'Do I really need chemotherapy?'" said Prof. Robert Stein, Lead Investigator, University College London. "OPTIMA answers this question with robust evidence. These study results can be practice-changing – we can now use the Prosigna test to predict which high-risk patients can safely avoid chemotherapy and its lasting side effects without compromising outcomes. That is a profound shift for patients and the clinicians who care for them." The Phase III prospective, randomized controlled trial compared standard of care – chemotherapy followed by hormone therapy – to treatment guided by Prosigna test results: patients with high ROR scores (>60) received chemotherapy followed by hormone therapy while those with low ROR scores (≤60) received hormone therapy alone. Key Trial Findings The OPTIMA trial results demonstrate: Chemotherapy can be safely avoided for many patients: The Prosigna test identified that 68% of patients with clinically high-risk node-positive breast cancer, who previously would have received chemotherapy, could safely forgo it entirely. These patients achieved 5-year cancer-free survival rates of 93.7% -- statistically noninferior to the 94.9% achieved with chemotherapy -- demonstrating that omitting treatment for these patients does not compromise outcomes or increase recurrence risk. Robust results across broadest range of high-risk subgroups: Non-inferiority was confirmed in previously under-studied populations where treatment guidance has been most uncertain, demonstrating that tumor biology, vs clinical factors alone, can guide chemotherapy decisions for: Premenopausal women treated with ovarian function suppression (HR 1.04; 90% CI 0.60–1.80) Patients with extensive nodal involvement (4–9 positive nodes, or pN2 disease) (HR 1.19; 95% CI 0.62–2.29) Highest level of prospective evidence: With 4,429 patients and 4.0-year median follow-up, OPTIMA provides Level 1A evidence, showing that the Prosigna test can accurately predict chemotherapy benefit and guide safe de-escalation across patient populations. The Impact on Patients with Breast Cancer Breast cancer remains the most commonly diagnosed cancer worldwide, affecting 1 in 8 women in the U.S.,1 with over 225,000 new HR+/HER2- breast cancer cases diagnosed annually.2 Treatment decisions play a critical role in preventing recurrence and improving long-term outcomes. For many of these patients, chemotherapy decisions have historically been driven by clinical factors alone – age, tumor size, and lymph node status – and its potential for multiple, severe side effects. Up to 43% of breast cancer survivors experience persistent nerve damage years after chemotherapy, with studies showing a broader range of treatment-related side effects impacting the majority of patients during and after care.3 The Prosigna test is a genomic test that uniquely combines intrinsic subtypes and proliferation score with clinical pathological factors to calculate a patient’s Risk of Recurrence (ROR) score. In OPTIMA, an ROR score < 60 enabled clinicians to identify patients who could safely avoid chemotherapy. The results from the OPTIMA trial are in a position to transform how clinicians approach breast cancer treatment decisions using the Prosigna ROR score to confidently de-escalate therapy in a high percentage of high-risk patients. "OPTIMA sets a new standard for how chemotherapy decisions are made in breast cancer," said Phillip Febbo, M.D., Chief Scientific and Medical Officer, Veracyte. "Prosigna now has the strongest prospective evidence of any genomic test to predict which patients with clinically high-risk hormone-receptor positive breast cancer can safely avoid chemotherapy. For patients, that means the option to choose a treatment with fewer unnecessary side effects, and for clinicians, the confidence to act on it." ASCO Annual Meeting Presentation The OPTIMA trial results are being presented this Saturday, May 30 at the 2026 ASCO Annual Meeting during the Breast Cancer—Local/Regional/Adjuvant Oral Abstract Session (1:15 PM CDT, Hall B1, Abstract 500). Prof. Robert C. Stein from University College London is presenting the findings, which will also be livestreamed via the ASCO conference platform. About the OPTIMA Trial OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) is an international, multicenter randomized controlled trial led by University College London and funded by U.K. National Institute for Health and Care Research. The independent study enrolled 4,429 women and men aged ≥40 years with ER-positive HER2-negative early breast cancer and 0–9 involved axillary lymph nodes. Participants were randomly assigned to either the control arm for standard chemotherapy followed by hormone therapy or to the Prosigna test-directed arm of standard chemotherapy followed by hormone therapy for patients with Prosigna high ROR test results (>60), versus hormone therapy alone for patients with Prosigna low ROR test results (≤60). All premenopausal women were required to have ovarian function suppression. About Veracyte Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter). Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to statements regarding the potential clinical utility, impact, and benefits of Veracyte’s Prosigna Breast Risk of Recurrence (ROR) test; the ability of the Prosigna Breast Test to guide adjuvant chemotherapy decisions in early-stage, ER-positive HER2-negative breast cancer patients, including identifying patients who may safely avoid chemotherapy and its side effects without compromising outcomes; the extent to which the results of the OPTIMA trial may be considered practice-changing or influence clinical decision-making; the potential for molecular testing to inform treatment decisions based on tumor biology rather than clinical factors alone; and the adoption and use of the Prosigna Breast Test in clinical practice across patient population. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed,” "ultimately," and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 26, 2026, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise. References:
1. https://www.nationalbreastcancer.org/breast-cancer-facts/
2. https://seer.cancer.gov/statfacts/html/breast-subtypes.html
3. https://onlinelibrary.wiley.com/doi/10.1002/cam4.4202?utm View source version on businesswire.com: https://www.businesswire.com/news/home/20260528130751/en/ Investors:
Kelly Gura
investors@veracyte.com Media:
Molly Cornbleet

OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast CancerMay 21, 2026 6:00 PM
Business Wire Additional Data from ENZAMET Study Show How Decipher Can Help Metastatic Prostate Cancer Patients Avoid Unnecessary Treatment and Enable More Personalized Care Veracyte, Inc. (NASDAQ: VCYT), a leading cancer diagnostics company, announced today that data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests will be presented at the 2026 ASCO Annual Meeting in Chicago, taking place May 29 – June 2. The OPTIMA and ENZAMET trial presentations are expected to provide practice-changing evidence demonstrating how Veracyte’s genomic tests can guide treatment decisions in both early-stage breast cancer and metastatic prostate cancer. The OPTIMA study is a prospective, randomized trial led by University College London (UCL) and supported by the National Institute for Health Research (NIHR). The study enrolled more than 4,400 patients and was designed to address a key clinical question: which patients would benefit from chemotherapy, and which may be able to safely avoid it, and its long-term toxicities. The study results demonstrating how the Prosigna test can guide adjuvant chemotherapy decisions in patients with high-risk breast cancer will be presented by Dr. Rob Stein of UCL and OPTIMA Trial Chief Investigator, on Saturday, May 30 during the breast cancer session. "The OPTIMA trial results represent a major milestone in precision breast oncology and will provide Level 1A evidence supporting Prosigna-guided treatment decisions," said Kelly Marcom, M.D., Veracyte’s medical director, Breast Cancer. "These findings have the potential to transform how clinicians treat a large population of patients with breast cancer, helping them to personalize their patient’s treatment choices using the genomic insights that the Prosigna test provides." The ENZAMET trial is an international, prospective, randomized study conducted by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Dr. Christopher Sweeney of South Australian Immunogenomics Cancer Institute, Adelaide University, will present data on Saturday, May 30 during the Genitourinary Cancer session on Decipher Prostate’s ability to predict treatment benefit with the chemotherapy docetaxel in metastatic, hormone-sensitive prostate cancer. The independent analysis evaluated how the Decipher test can help identify which patients are most likely to benefit from treatment intensification with triplet therapy (docetaxel to standard of cancer hormonal therapy). "Together, these studies provide practice-changing evidence supporting the use of Veracyte’s tests in guiding treatment decisions across cancer types," said Phillip Febbo, M.D., Veracyte’s chief scientific and medical officer. "In practice, this means clinicians can more confidently match treatment intensity to individual patient risk, helping ensure the right level of care while avoiding unnecessary treatment and its side effects, for both breast and prostate cancer patients." Additional research to be presented at ASCO supports the company's mission to transform cancer care for patients all over the world. Oral Presentations at ASCO 2026 Annual Meeting Title: First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer Presenter: Robert Stein, PhD, MBBChir, FRC, National Institute for Health Research University College London Hospitals Biomedical Research Centre Session Title: Breast Cancer—Local/Regional/Adjuvant Date/Time: Saturday, May 30, 2026, 1:15 PM CT Location: Hall B1 Title: Clinico-Transcriptomic Risk Stratification to Guide Abiraterone Treatment Intensification in High-Risk Prostate Cancer: A Combined Analysis of NRG/RTOG 9202, 9413, 9902, and 0521 Presenter: Krishnan R Patel, MD, MHS, Radiation Oncology Branch, National Cancer Institute, NIH Session Title: Genitourinary Cancer—Prostate, Testicular, and Penile Date/Time: Saturday, May 30, 2026, 3:00 PM CT Location: Hall D1 Title: Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study Presenter: Christopher Sweeney, MBBS, South Australian Immunogenomics Cancer Institute, Adelaide University Session Title: Genitourinary Cancer—Prostate, Testicular, and Penile Date/Time: Saturday, May 30, 2026, 3:12 PM CT Location: Hall D1 Title: Genomic classifier–driven NCCN risk reclassification to track distinct transcriptomic signatures in early prostate cancer Presenter: Daniel Keizman, MD, Tel Aviv Sourasky Medical Center, Israel Session Title: Genitourinary Cancer—Prostate, Testicular, and Penile Date/Time: Sunday, May 31, 2026, 4:36 PM CT Location: Hall D1 Additional Posters at ASCO Abstract #1660 | Poster bd #578: Titled: Practice patterns and outcomes by genomic risk in octogenarians with high-risk localized prostate cancer: a national real-world data analysis. Presenter: James Janopaul-Naylor – Saturday May 30, 2026 at 9:00 AM CDT, Hall A Abstract #4619 | Poster bd #98: Titled: Neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer: Final results and biomarker analyses of the SURE-01 trial. Presenter: Brigida A. Maiorano – Sunday, May 31, 2026 at 9:00 AM CDT, Hall A Abstract #5114 | Poster bd #209: Titled: Assessing the Clinical and Biological Associations Between Artera Multimodal Artificial Intelligence (MMAI) and Decipher Genomic Classifier (GC) in Localized Prostate Cancer (PCa). Presenter: Boon Hao Hong – Sunday, May 31, 2026 at 9:00 AM CDT, Hall A Abstract #4617 | Poster bd #96: Titled: Molecular characterization of residual disease post-neoadjuvant sacituzumab govitecan (SG), pembrolizumab, or their combination in patients with muscle-invasive bladder cancer (MIBC). Presenter: Andrea Necchi – Sunday, May 31, 2026 at 9:00 AM CDT, Hall A For more information, stop by Veracyte’s booth #13069 at the ASCO Annual Meeting or visit the company’s website here. About Veracyte Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter). Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements regarding the potential clinical utility, impact, and benefits of Veracyte’s Prosigna Breast Risk of Recurrence (ROR) test and Decipher Prostate test; the ability of these tests to guide treatment decisions in both early-stage breast cancer and metastatic prostate cancer, including identifying patients who may benefit from or avoid certain therapies or treatment intensification; and the extent to which data from the OPTIMA and ENZAMET trials may be considered practice-changing or influence clinical decision-making. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed,” “ultimately,” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 26, 2026 and our subsequent Quarterly Reports on Form 10-Q. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise. View source version on businesswire.com: https://www.businesswire.com/news/home/20260521430337/en/ Investors:
Kelly Gura
investors@veracyte.com Media:
Molly Cornbleet

Veracyte to Participate in Upcoming Investor ConferencesMay 19, 2026 4:05 PM
Business Wire Veracyte, Inc. (Nasdaq: VCYT) announced today that the company will be participating in the following investor conferences. William Blair 46th Annual Growth Stock Conference – Chicago, IL
Presentation on Tuesday, June 2nd at 2:00 p.m. Central Time 2026 Jefferies Global Healthcare Conference – New York, NY
Fireside chat on Thursday, June 4th at 8:10 a.m. Eastern Time Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days after each live presentation broadcast. About Veracyte Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter). View source version on businesswire.com: https://www.businesswire.com/news/home/20260519940364/en/ Investors
Kelly Gura
investors@veracyte.com Media:
Molly Cornbleet
media@veracyte.com Original: Veracyte to Participate in Upcoming Investor Conferences

Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026April 14, 2026 4:05 PM
Business Wire
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 after the close of market on Tuesday, May 5, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.


The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/293q6w6a. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.


The conference call dial-ins can be accessed by registering via this link.


About Veracyte


Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

View source version on businesswire.com: https://www.businesswire.com/news/home/20260414666656/en/
Investors

Kelly Gura

investors@veracyte.com

(619) 393-1545


Media

Molly Cornbleet

media@veracyte.com


Original: Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026

Veracyte Names Kevin Haas as Chief Development and Technology OfficerMarch 16, 2026 4:15 PM
Business Wire
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership role designed to advance and scale the company’s global product development strategy. Dr. Haas will join Veracyte on March 24, 2026, and he will be responsible for overseeing the company’s end-to-end product development, spanning diagnostic assay development, software and bioinformatics, as well as the product development program office.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316934398/en/Veracyte Names Kevin Haas as Chief Development and Technology Officer
As Veracyte’s pipeline expands into whole-genome minimal residual disease (MRD) and other multi-omics applications, product development requires integrated capabilities across assays, software, AI, and next-generation informatics to support solutions from diagnosis to disease management. In this role, Dr. Haas will lead these efforts to deliver high-quality laboratory-developed tests (LDTs) and global in vitro diagnostic (IVD) products. He will bring these capabilities together to accelerate innovation and support the company’s global portfolio.


“Kevin is an accomplished product development and software leader with a track record of advancing diagnostic innovations and platform technologies,” said Marc Stapley, Veracyte’s Chief Executive Officer. “His experience across software engineering, data science, and assay development will be critical as we execute on a growing pipeline of tests in development and expand our portfolio to benefit clinicians and patients worldwide.”


Dr. Haas has more than 15 years of life sciences industry experience, leading teams across technology, research, and development. Most recently, he served as Chief Technology Officer at Myriad Genetics, where he led the development of the company’s precision medicine platform and digital health strategy. Prior to that, Dr. Haas was Senior Vice President of Engineering at Myriad and Vice President of Bioinformatics at Myriad Women's Health. Before joining Myriad, he held leadership roles in lab engineering and bioinformatics at Counsyl.


Dr. Haas has expertise in creating automated lab technology and AI systems to derive insights from genomics data, and in launching scalable molecular assays. He received a B.S. from University of Wisconsin-Madison and a Ph.D. in chemical engineering from University of California-Berkeley, where he worked on molecular simulation and machine learning to study protein dynamics.


“I am excited to join Veracyte at a time when the company is launching several exciting new tests, which is just the start of an incredibly strong development pipeline,” said Dr. Haas. “The opportunity to help advance this breadth of innovation and development capabilities by bringing new diagnostic solutions for patients facing cancer is incredibly meaningful.”


About Veracyte


Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).


Cautionary Note Regarding Forward-Looking Statements


This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 26, 2026, and our subsequent Quarterly Reports on Form 10-Q. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260316934398/en/
Investors:

Shayla Gorman

investors@veracyte.com


Media:

Molly Cornbleet

media@veracyte.com


Original: Veracyte Names Kevin Haas as Chief Development and Technology Officer

Veracyte Announces Fourth Quarter and Full Year 2025 Financial ResultsFebruary 25, 2026 4:05 PM
Business Wire
Grew fourth quarter total revenue to $140.6 million, an increase of 19%

Grew fourth quarter testing revenue to $135.8 million, an increase of 21%


Conference call and webcast today at 4:30 p.m. ET


Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the fourth quarter and full year ended December 31, 2025.


“We delivered an exceptional finish to 2025, with strong double-digit growth across both Decipher and Afirma and more than 45,000 patients served with our core testing business in the quarter,” said Marc Stapley, Veracyte’s chief executive officer. “We are achieving this growth while maintaining best-in-class profitability, with more than $50 million of cash generated from operations in the quarter. Looking ahead, 2026 will be an exciting year as we launch Prosigna as an LDT and TrueMRD, expanding our reach to more patients across the continuum of care while also continuing to invest in clinical evidence that reinforces the value and utility of our portfolio.”


Key Fourth Quarter 2025 Financial Highlights


For the three-month period ended December 31, 2025, as compared to the same period in 2024:



Increased total revenue by 19% to $140.6 million and testing revenue by 21% to $135.8 million.



Increased total volume by 16% to 48,019 tests and testing volume by 16% to 45,516 tests.



Grew Decipher revenue by 27% to $85.6 million and Afirma revenue by 16% to $47.9 million.



Grew Decipher volume by 21% to approximately 27,200 tests and Afirma volume by 12% to approximately 18,250 tests.



Recorded GAAP net income of $41.1 million, or 29.3% of revenue, and delivered adjusted EBITDA of $42.3 million, or 30.1% of revenue.



Generated $52.6 million of cash from operations.



Key Full Year 2025 Financial Highlights


For the twelve-month period ended December 31, 2025, as compared to the same period in 2024:



Increased total revenue by 16% to $517.1 million and testing revenue by 18% to $493.2 million.



Increased total volume by 18% to 179,528 tests and testing volume by 19% to 169,714 tests.



Grew Decipher revenue by 27% to $310.7 million and Afirma revenue by 9% to $172.9 million.



Grew Decipher volume by 27% to approximately 102,000 tests and Afirma volume by 11% to approximately 67,700 tests.



Recorded GAAP net income of $66.4 million, or 12.8% of revenue, and delivered adjusted EBITDA of $142.5 million, or 27.6% of revenue.



Generated $136.3 million of cash from operations to end the year with $412.9 million of cash, cash equivalents, and short-term investments as of December 31, 2025.



Key Business Highlights



Announced over 15 abstracts featuring Decipher Prostate and Decipher Bladder that will be presented at the ASCO GU meeting this week, including results for Decipher Bladder from the SURE-02, NURE-combo, and BLASST-01 trials.



Highlighted the upcoming TrueMRD Muscle-Invasive Bladder Cancer (MIBC) test’s inclusion in the HCRN GU 20-444 response guided bladder-sparing trial, with data planned to be presented at ASCO GU.



Completed the transition of all Afirma samples to the v2 transcriptome to improve the efficiency of the Afirma testing business and enable more patients to receive a result, while providing a platform for future product launches, such as Prosigna LDT.



A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading "Note Regarding Use of Non-GAAP Financial Measures."


Fourth Quarter 2025 Financial Results


Total revenue for the fourth quarter of 2025 was $140.6 million, an increase of 19% compared to $118.6 million reported in the fourth quarter of 2024. Testing revenue was $135.8 million, an increase of 21% compared to $112.2 million in the fourth quarter of 2024, driven by growth in our Decipher Prostate and Afirma tests. Product revenue was $3.8 million, an increase of 27% compared to $3.0 million in the fourth quarter of 2024. Biopharmaceutical and other revenue was $1.0 million, a decrease compared to $3.5 million in the fourth quarter of 2024 given the restructuring and liquidation proceedings of Veracyte SAS.


Total gross margin for the fourth quarter of 2025 was 72.5%, compared to 66.4% in the fourth quarter of 2024. Non-GAAP gross margin was 75.1%, compared to 69.3% in the fourth quarter of 2024.


Operating expenses were $64.8 million for the fourth quarter of 2025. Non-GAAP operating expenses grew 12% to $65.1 million compared to $57.9 million in the fourth quarter of 2024.


Net income for the fourth quarter of 2025 was $41.1 million, an improvement of 705% compared to the fourth quarter of 2024, representing 29.3% of revenue compared to 4.3% in the same period in 2024. Diluted net earnings per common share was $0.51, an improvement of $0.45 compared to the fourth quarter of 2024. Non-GAAP diluted net earnings per common share was $0.53, an improvement of $0.17 compared to the fourth quarter of 2024. Net cash provided by operating activities in the fourth quarter of 2025 was $52.6 million, an improvement of $28.1 million compared to the same period in 2024.


Adjusted EBITDA for the fourth quarter of 2025 was $42.3 million, an improvement of 62% compared to the fourth quarter of 2024, representing 30.1% of revenue compared to 22.0% of revenue in the same period of 2024.


Full Year 2025 Financial Results


Total revenue for 2025 was $517.1 million, an increase of 16% compared to $445.8 million reported in 2024. Testing revenue was $493.2 million, an increase of 18% compared to $419.0 million in 2024, driven by growth in our Decipher Prostate and Afirma tests. Product revenue was $14.3 million, an increase of 5% compared to $13.7 million in 2024. Biopharmaceutical and other revenue was $9.7 million, a decrease compared to $13.2 million in 2024 given the restructuring and liquidation proceedings of Veracyte SAS.


Total gross margin for the full year 2025 was 70.1%, compared to 66.9% in 2024. Non-GAAP gross margin was 72.9%, compared to 70.0% in 2024.


Operating expenses were $304.8 million for the full year 2025. Non-GAAP operating expenses grew 7% to $244.6 million compared to $227.6 million in 2024.


Net income for the full year 2025 was $66.4 million, an improvement of 175% compared to 2024, representing 12.8% of revenue compared to 5.4% in 2024. Diluted net earnings per common share was $0.82, an improvement of $0.51 compared to 2024. Non-GAAP diluted net earnings per common share was $1.78, an improvement of $0.59 compared to 2024. Net cash provided by operating activities in 2025 was $136.3 million, an improvement of $61.2 million compared to 2024.


Adjusted EBITDA for the full year of 2025 was $142.5 million, an improvement of 55% compared to 2024, representing 27.6% of revenue compared to 20.6% of revenue in 2024.


2026 Financial Outlook


The company is reiterating 2026 total revenue guidance of 10% to 13% growth, or $570 million to $582 million, driven by testing revenue guidance of 14% to 16% growth, or $560 million to $570 million, excluding the contribution from new tests.


Further, adjusted EBITDA margin is expected to be approximately 25%.


The company is unable to provide a quantitative reconciliation of expected adjusted EBITDA margin to the most directly comparable forward-looking GAAP measure without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, that are dependent on various factors, are out of the company’s control, or that cannot be reasonably predicted. Such adjustments include, but are not limited to, acquisition-related expenses, and other adjustments. Any associated estimate of these items and their impact on GAAP performance for the guidance period could vary materially. For more information on the non-GAAP financial measures, please refer to the section titled “Note Regarding Use of Non-GAAP Financial Measures” at the end of this press release.


Conference Call and Webcast Details


Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/motsphxv/. The webcast should be accessed 10 minutes prior to the conference call start time. A replay of the webcast will be available for one year following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.


The conference call dial-in can be accessed by registering via the following link:

https://register-conf.media-server.com/register/BI4553e156b9684d869faee6cbab4cb045


About Veracyte


Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).


Cautionary Note Regarding Forward-Looking Statements


This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with respect to our 2026 financial and operating results; and our intentions with respect to our tests and products, including upcoming product launches. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “could,” “would,” “will,” “enable,” “positioned,” “offers,” “designed,” “ultimately,” “strategic,” “outlook,” “guidance,” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: our ability to launch, commercialize and receive reimbursement for our products; our ability to execute on our business strategies relating to the C2i Genomics acquisition, integration of the business and the realization of expected benefits and synergies; our ability to demonstrate the validity and utility of our genomic tests and biopharma and other offerings; our ability to continue executing on our business plan; our ability to continue to scale our global operations and enhance our internal control environment; the impact of the war in Ukraine and other regional conflicts on European economies; the impact of foreign currency fluctuations, volatile interest rates, inflation, the impact of legislation and policies enacted by the current U.S. administration; turmoil in the global banking and finance system; the ongoing conflict in the Middle East; and the performance and utility of our tests in the clinical environment. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 28, 2025, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.


Note Regarding Use of Non-GAAP Financial Measures


In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release and the accompanying tables contain, and reference certain non-GAAP results including non-GAAP gross margin, non-GAAP operating expenses, adjusted EBITDA, adjusted EBITDA as a percentage of revenue (also referred to as adjusted EBITDA margin), non-GAAP net income, and non-GAAP earnings per share (EPS) and non-GAAP weighted average shares outstanding. These non-GAAP financial measures are not meant to be considered superior to or a substitute for financial measures calculated in accordance with GAAP, and investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool.


We use non-GAAP financial measures to internally evaluate and analyze financial results. We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and enable comparison of our financial results with other public companies, many of which present similar non-GAAP financial measures. However, the non-GAAP financial measures we present may be different from those used by other companies, including similarly titled measures.


We compute these non-GAAP measures by adjusting the applicable GAAP measure to remove the impact of certain recurring and non-recurring charges and gains and to adjust for the impact of income tax items related to such adjustments to our GAAP financial statements. In particular, we exclude amortization of acquired intangible assets, acquisition-related expenses relating to our acquisitions of Decipher Biosciences, HalioDx and C2i Genomics, impairment charges associated with the nCounter license and other biopharmaceutical services related to HalioDx intangible assets, all stock-based compensation and certain costs related to restructuring from all of our non-GAAP financial measures as well as depreciation and income tax items from our adjusted EBITDA and adjusted EBITDA as a percentage of revenue. Beginning in the second quarter of 2024, we changed our non-GAAP policy to exclude all stock-based compensation to align with our peers and we have also excluded all stock-based compensation from our prior period non-GAAP financial measures. Management has excluded the effects of these items in non-GAAP financial measures to help investors gain a better understanding of the core operating results and future prospects of the company, consistent with how management measures and forecasts the company’s performance, especially when comparing such results to previous periods or forecasts. The company encourages investors to carefully consider its results under GAAP, together with its supplemental non-GAAP information and the reconciliation between these presentations. See “Reconciliation of U.S. GAAP to Non-GAAP Financial Measures” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure.




VERACYTE, INC.








CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS








(Unaudited)








(In thousands, except share and per share amounts)








 





 

 






 






 






 






 






 






 








 





 

Three Months Ended

December 31






 






Twelve Months Ended

December 31








 





 

2025






 






2024






 






2025






 






2024








Revenue:





 

 






 






 






 






 






 






 








Testing revenue





 

$






135,826






 






 






$






112,152






 






 






$






493,154






 






$






418,961








Product revenue





 

 






3,848






 






 






 






3,019






 






 






 






14,327






 






 






13,650








Biopharmaceutical and other revenue





 

 






962






 






 






 






3,461






 






 






 






9,664






 






 






13,153








Total revenue





 

 






140,636






 






 






 






118,632






 






 






 






517,145






 






 






445,764








 





 

 






 






 






 






 






 






 








Cost of revenue: (1)





 

 






 






 






 






 






 






 








Cost of testing revenue





 

 






33,118






 






 






 






31,645






 






 






 






127,562






 






 






114,573








Cost of product revenue





 

 






2,621






 






 






 






2,800






 






 






 






8,807






 






 






9,110








Cost of biopharmaceutical and other revenue





 

 






217






 






 






 






2,622






 






 






 






7,578






 






 






12,384








Intangible asset amortization - cost of revenue





 

 






2,707






 






 






 






2,811






 






 






 






10,666






 






 






11,552








Total cost of revenue





 

 






38,663






 






 






 






39,878






 






 






 






154,613






 






 






147,619








Gross profit





 

 






101,973






 






 






 






78,754






 






 






 






362,532






 






 






298,145








Operating expenses: (1)





 

 






 






 






 






 






 






 








Research and development





 

 






20,849






 






 






 






19,290






 






 






 






70,814






 






 






69,294








Selling and marketing





 

 






25,940






 






 






 






24,824






 






 






 






100,165






 






 






95,434








General and administrative





 

 






17,367






 






 






 






26,913






 






 






 






110,784






 






 






110,610








Impairment of assets





 

 






—






 






 






 






2,754






 






 






 






20,505






 






 






3,368








Intangible asset amortization - operating expenses





 

 






622






 






 






 






798






 






 






 






2,487






 






 






3,297








Total operating expenses





 

 






64,778






 






 






 






74,579






 






 






 






304,755






 






 






282,003








Income from operations





 

 






37,195






 






 






 






4,175






 






 






 






57,777






 






 






16,142








Other income (loss), net





 

 






3,439






 






 






 






(732






)






 






 






10,424






 






 






9,602








Income before income taxes





 

 






40,634






 






 






 






3,443






 






 






 






68,201






 






 






25,744








Income tax provision (benefit)





 

 






(515






)






 






 






(1,670






)






 






 






1,848






 






 






1,606








Net income





 

$






41,149






 






 






$






5,113






 






 






$






66,353






 






$






24,138








Earnings per share:





 

 






 






 






 






 






 






 








Basic





 

$






0.52






 






 






$






0.07






 






 






$






0.84






 






$






0.32








Diluted





 

$






0.51






 






 






$






0.06






 






 






$






0.82






 






$






0.31








Shares used to compute earnings per common share:





 

 






 






 






 






 






 






 








Basic





 

 






79,178,087






 






 






 






77,608,924






 






 






 






78,584,291






 






 






76,484,759








Diluted





 

 






81,387,089






 






 






 






79,905,412






 






 






 






80,573,140






 






 






78,163,217









1.






 






Cost of revenue, research and development, sales and marketing and general and administrative expenses include the following stock-based compensation related expenses:









 





 

Three Months Ended

December 31






 






Twelve Months Ended

December 31








 





 

2025






 






2024






 






2025






 






2024








Cost of revenue





 

$






618






 






$






641






 






$






2,286






 






$






2,319








Research and development





 

 






1,895






 






 






1,896






 






 






7,919






 






 






7,511








Selling and marketing





 

 






2,060






 






 






1,872






 






 






8,317






 






 






6,897








General and administrative





 

 






6,328






 






 






5,220






 






 






25,079






 






 






19,522








Total stock-based compensation expense





 

$






10,901






 






$






9,629






 






$






43,601






 






$






36,249









VERACYTE, INC.








CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS)








(Unaudited)








(In thousands)








 





 

 






 






 






 






 






 






 








 





 

Three Months Ended

December 31






 






Twelve Months Ended

December 31








 





 

2025






 






2024






 






2025






 






2024








Net income





 

$






41,149






 






$






5,113






 






 






$






66,353






 






$






24,138






 








Other comprehensive income (loss):





 

 






 






 






 






 






 






 








Change in currency translation adjustments





 

 






8






 






 






(14,808






)






 






 






19,583






 






 






(12,072






)








Release of accumulated translation adjustment





 

 






—






 






 






—






 






 






 






8,295






 






 






—






 








Other comprehensive income (loss)





 

 






8






 






 






(14,808






)






 






 






27,878






 






 






(12,072






)








Net comprehensive income (loss)





 

$






41,157






 






$






(9,695






)






 






$






94,231






 






$






12,066










VERACYTE, INC.








CONDENSED CONSOLIDATED BALANCE SHEETS








(In thousands)








 





 

 






 






 








 





 

December 31,






 






December 31,








 





 

2025






 






2024








 





 

(Unaudited)






 






(See Note 1)








Assets





 

 






 






 








Current assets:





 

 






 






 








Cash and cash equivalents





 

$






362,578






 






$






239,087








Short-term investments





 

 






50,311






 






 






50,354








Accounts receivable





 

 






44,660






 






 






46,525








Supplies and inventory





 

 






20,546






 






 






21,750








Prepaid expenses and other current assets





 

 






10,281






 






 






14,551








Total current assets





 

 






488,376






 






 






372,267








Property, plant and equipment, net





 

 






22,192






 






 






22,953








Right-of-use assets, operating leases





 

 






36,599






 






 






48,189








Intangible assets, net





 

 






89,148






 






 






102,301








Goodwill





 

 






767,154






 






 






745,800








Restricted cash





 

 






1,648






 






 






1,544








Other assets





 

 






902






 






 






6,981








Total assets





 

$






1,406,019






 






$






1,300,035








Liabilities and Stockholders’ Equity





 

 






 






 








Current liabilities:





 

 






 






 








Accounts payable





 

$






4,593






 






$






8,634








Accrued liabilities





 

 






48,801






 






 






43,826








Current portion of deferred revenue





 

 






1,160






 






 






1,673








Current portion of acquisition-related contingent consideration





 

 






1,332






 






 






16,981








Current portion of operating lease liabilities





 

 






4,051






 






 






7,500








Current portion of other liabilities





 

 






—






 






 






19








Total current liabilities





 

 






59,937






 






 






78,633








Deferred tax liability





 

 






646






 






 






1,227








Acquisition-related contingent consideration, net of current portion





 

 






257






 






 






561








Operating lease liabilities, net of current portion





 

 






35,603






 






 






43,237








Other liabilities





 

 






—






 






 






411








Total liabilities





 

 






96,443






 






 






124,069








Total stockholders' equity





 

 






1,309,576






 






 






1,175,966








Total liabilities and stockholders’ equity





 

$






1,406,019






 






$






1,300,035









1.






 






The condensed consolidated balance sheet at December 31, 2024 has been derived from the audited financial statements at that date included in the company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 28, 2025.









VERACYTE, INC.








CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS








(Unaudited)








(In thousands)








 





 

 






 






 








 





 

Twelve Months Ended

December 31








 





 

2025






 






2024








Operating activities





 

 






 






 








Net income





 

$






66,353






 






 






$






24,138






 








Adjustments to reconcile net income to net cash provided by operating activities:





 

 






 






 








Depreciation and amortization





 

 






21,415






 






 






 






23,459






 








Loss on disposal of property, plant and equipment





 

 






15






 






 






 






202






 








Stock-based compensation





 

 






43,601






 






 






 






36,249






 








Deferred income taxes





 

 






(581






)






 






 






(233






)








Non-cash lease expense





 

 






2,991






 






 






 






4,955






 








Revaluation of acquisition-related contingent consideration





 

 






(15,295






)






 






 






2,167






 








Amortization of discount on short-term investments





 

 






(3,270






)






 






 






(354






)








Impairment loss





 

 






20,505






 






 






 






3,368






 








Non-cash loss on deconsolidation of subsidiary





 

 






6,708






 






 






 






—






 








Effect of foreign currency on operations





 

 






(3,834






)






 






 






2,110






 








Changes in operating assets and liabilities:





 

 






 






 








Accounts receivable





 

 






(708






)






 






 






(6,405






)








Supplies and inventory





 

 






(2,861






)






 






 






(5,871






)








Prepaid expenses and other current assets





 

 






(2,054






)






 






 






(1,296






)








Other assets





 

 






525






 






 






 






(1,222






)








Operating lease liabilities





 

 






(2,480






)






 






 






(5,407






)








Accounts payable





 

 






(1,039






)






 






 






(4,305






)








Accrued liabilities and deferred revenue





 

 






6,316






 






 






 






3,541






 








Net cash provided by operating activities





 

 






136,307






 






 






 






75,096






 








Investing activities





 

 






 






 








Purchase of short-term investments





 

 






(149,998






)






 






 






(50,000






)








Proceeds from maturity of short-term investments





 

 






153,311






 






 






 






—






 








Loss on deconsolidation of subsidiary - cash





 

 






(2,845






)






 






 






—






 








Acquisition of C2i, net of cash acquired





 

 






—






 






 






 






5,012






 








Purchases of property, plant and equipment





 

 






(9,677






)






 






 






(11,287






)








Net cash used in investing activities





 

 






(9,209






)






 






 






(56,275






)








Financing activities





 

 






 






 








Payment of contingent consideration for acquisition





 

 






—






 






 






 






(4,500






)








Payment of taxes on vested restricted stock units





 

 






(18,304






)






 






 






(10,589






)








Proceeds from the exercise of common stock options and employee stock purchases





 

 






14,082






 






 






 






19,993






 








Net cash (used in) provided by financing activities





 

 






(4,222






)






 






 






4,904






 








Increase in cash, cash equivalents and restricted cash





 

 






122,876






 






 






 






23,725






 








Effect of foreign currency on cash, cash equivalents and restricted cash





 

 






719






 






 






 






(424






)








Net increase in cash, cash equivalents and restricted cash





 

 






123,595






 






 






 






23,301






 








Cash, cash equivalents and restricted cash at beginning of year





 

 






240,631






 






 






 






217,330






 








Cash, cash equivalents and restricted cash at end of year





 

$






364,226






 






 






$






240,631






 









CASH, CASH EQUIVALENTS AND RESTRICTED CASH








(Unaudited)








(In thousands)








 





 

 






 






 








 





 

December 31,






 






December 31,








 





 

2025






 






2024








Cash and cash equivalents





 

$






362,578






 






$






239,087








Restricted cash





 

 






1,648






 






 






1,544








Total cash, cash equivalents and restricted cash





 

$






364,226






 






$






240,631









VERACYTE, INC.








RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES








(Unaudited)








(In thousands)








 





 

 






 






 






 






 






 






 








 





 

Three Months Ended

December 31






 






Twelve Months Ended

December 31








 





 

 






2025






 






 






 






2024






 






 






 






2025






 






 






 






2024






 








Reconciliation of Non-GAAP Cost of Revenue:





 

 






 






 






 






 






 






 








GAAP cost of testing revenue





 

$






33,118






 






 






$






31,645






 






 






$






127,562






 






 






$






114,573






 








Stock-based compensation expense





 

 






(616






)






 






 






(562






)






 






 






(2,159






)






 






 






(1,973






)








Acquisition related expenses (1)





 

 






—






 






 






 






—






 






 






 






—






 






 






 






(60






)








Other adjustments (2)





 

 






—






 






 






 






—






 






 






 






—






 






 






 






(6






)








Non-GAAP cost of testing revenue





 

$






32,502






 






 






$






31,083






 






 






$






125,403






 






 






$






112,534






 








 





 

 






 






 






 






 






 






 








GAAP cost of product revenue





 

$






2,621






 






 






$






2,800






 






 






$






8,807






 






 






$






9,110






 








Stock-based compensation expense





 

 






—






 






 






 






(1






)






 






 






(2






)






 






 






(4






)








Acquisition related expenses (1)





 

 






—






 






 






 






—






 






 






 






—






 






 






 






—






 








Other adjustments (2)





 

 






(281






)






 






 






—






 






 






 






(1,731






)






 






 






—






 








Non-GAAP cost of product revenue





 

$






2,340






 






 






$






2,799






 






 






$






7,074






 






 






$






9,106






 








 





 

 






 






 






 






 






 






 








GAAP cost of biopharmaceutical and other revenue





 

$






217






 






 






$






2,622






 






 






$






7,578






 






 






$






12,384






 








Stock-based compensation expense





 

 






(2






)






 






 






(78






)






 






 






(125






)






 






 






(342






)








Acquisition related expenses (1)





 

 






—






 






 






 






—






 






 






 






—






 






 






 






—






 








Other adjustments (2)





 

 






—






 






 






 






—






 






 






 






—






 






 






 






—






 








Non-GAAP cost of biopharmaceutical and other revenue





 

$






215






 






 






$






2,544






 






 






$






7,453






 






 






$






12,042






 








 





 

 






 






 






 






 






 






 








Reconciliation of Non-GAAP Gross Margin:





 

 






 






 






 






 






 






 








GAAP Gross Profit





 

$






101,973






 






 






$






78,754






 






 






$






362,532






 






 






$






298,145






 








GAAP Gross Margin





 

 






72.5






%






 






 






66.4






%






 






 






70.1






%






 






 






66.9






%








Amortization of intangible assets





 

 






2,707






 






 






 






2,811






 






 






 






10,666






 






 






 






11,552






 








Stock-based compensation expense





 

 






618






 






 






 






641






 






 






 






2,286






 






 






 






2,319






 








Acquisition related expenses (1)





 

 






—






 






 






 






—






 






 






 






—






 






 






 






60






 








Other adjustments (2)





 

 






281






 






 






 






—






 






 






 






1,731






 






 






 






6






 








Non-GAAP Gross Profit





 

$






105,579






 






 






$






82,206






 






 






$






377,215






 






 






$






312,082






 








Non-GAAP Gross Margin





 

 






75.1






%






 






 






69.3






%






 






 






72.9






%






 






 






70.0






%









1.






 






Includes transaction-related expenses and post-combination compensation expenses. For the twelve months ended December 31, 2024, adjustments consist primarily of transaction-related expenses associated with the acquisition of C2i Genomics Ltd. (“C2i Genomics”).








2.






 






For the three months ended December 31, 2025, adjustments primarily include expense related to the restructuring of Veracyte SAS ($0.3 million). For the twelve months ended December 31, 2025, adjustments include additional expenses related to the restructuring and liquidation proceedings of Veracyte SAS. For the twelve months ended December 31, 2024, adjustments primarily include expense related to restructuring costs associated with portfolio prioritization.









VERACYTE, INC.








RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES








(Unaudited)








(In thousands)








 





 

 






 






 






 






 






 






 








 





 

Three Months Ended

December 31






 






Twelve Months Ended

December 31








 





 

2025






 






2024






 






2025






 






2024








Reconciliation of Non-GAAP Operating Expenses:





 

 






 






 






 






 






 






 








GAAP research and development





 

$






20,849






 






 






$






19,290






 






 






$






70,814






 






 






$






69,294






 








Stock-based compensation expense





 

 






(1,895






)






 






 






(1,896






)






 






 






(7,919






)






 






 






(7,511






)








Acquisition related expenses (1)





 

 






—






 






 






 






—






 






 






 






—






 






 






 






62






 








Other adjustments (2)





 

 






—






 






 






 






—






 






 






 






—






 






 






 






(271






)








Non-GAAP research and development





 

$






18,954






 






 






$






17,394






 






 






$






62,895






 






 






$






61,574






 








 





 

 






 






 






 






 






 






 








GAAP sales and marketing





 

$






25,940






 






 






$






24,824






 






 






$






100,165






 






 






$






95,434






 








Stock-based compensation expense





 

 






(2,060






)






 






 






(1,872






)






 






 






(8,317






)






 






 






(6,897






)








Acquisition related expenses (1)





 

 






—






 






 






 






—






 






 






 






—






 






 






 






(124






)








Other adjustments (2)





 

 






—






 






 






 






—






 






 






 






—






 






 






 






(1,087






)








Non-GAAP sales and marketing





 

$






23,880






 






 






$






22,952






 






 






$






91,848






 






 






$






87,326






 








 





 

 






 






 






 






 






 






 








GAAP general and administrative





 

$






17,367






 






 






$






26,913






 






 






$






110,784






 






 






$






110,610






 








Stock-based compensation expense





 

 






(6,328






)






 






 






(5,220






)






 






 






(25,079






)






 






 






(19,522






)








Acquisition related expenses (1)





 

 






12,564






 






 






 






(928






)






 






 






11,971






 






 






 






(5,862






)








Other adjustments (2)





 

 






(1,309






)






 






 






(3,196






)






 






 






(7,839






)






 






 






(6,564






)








Non-GAAP general and administrative





 

$






22,294






 






 






$






17,569






 






 






$






89,837






 






 






$






78,662






 








 





 

 






 






 






 






 






 






 








GAAP total operating expenses





 

$






64,778






 






 






$






74,579






 






 






$






304,755






 






 






$






282,003






 








Amortization of intangible assets





 

 






(622






)






 






 






(798






)






 






 






(2,487






)






 






 






(3,297






)








Stock-based compensation expense





 

 






(10,283






)






 






 






(8,988






)






 






 






(41,315






)






 






 






(33,930






)








Acquisition related expenses (1)





 

 






12,564






 






 






 






(961






)






 






 






11,971






 






 






 






(6,571






)








Other adjustments (2)





 

 






(1,309






)






 






 






(5,917






)






 






 






(28,344






)






 






 






(10,643






)








Non-GAAP total operating expenses





 

$






65,128






 






 






$






57,915






 






 






$






244,580






 






 






$






227,562






 









1.






 






Includes transaction-related expenses and post-combination compensation expenses. For the three months ended December 31, 2025, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to the NanoString Technologies, Inc. ("NanoString") transaction ($0.7 million) and contingent consideration associated with the C2i Genomics acquisition ($11.9 million). For the three months ended December 31, 2024, adjustments consist primarily of transaction-related expenses associated with the acquisition of C2i Genomics ($1.0 million). For the twelve months ended December 31, 2025, adjustments consist primarily of transaction-related expenses associated with the acquisition of C2i Genomics ($10.3 million) and NanoString contingent consideration ($1.7 million). For the twelve months ended December 31, 2024, adjustments consist primarily of transaction-related expenses associated with the acquisition of C2i Genomics.








2.






 






For the three months ended December 31, 2025, adjustments primarily include expenses related to the restructuring and liquidation proceedings of Veracyte SAS ($1.1 million) and other legal proceedings ($0.2 million). For the three months ended December 31, 2024, adjustments primarily include expense related to Veracyte SAS site investment review ($3.2 million) and expense related to the impairment charge associated with HalioDx ($2.7 million). For the twelve months ended December 31, 2025, adjustments include additional expenses related to Veracyte SAS impairment loss ($20.5 million), the restructuring and liquidation proceedings of Veracyte SAS ($8.7 million), and other legal proceedings ($0.8 million), partially offset by adjustments related to vendor legal settlement ($2.8 million) and restructuring costs ($0.1 million). For the twelve months ended December 31, 2024, adjustments primarily include expense related to restructuring costs associated with a reduction in our Biopharmaceutical and Other segment and with portfolio prioritization, expense related to Veracyte SAS site investment review and expense related to the impairment charge associated with HalioDx. 









VERACYTE, INC.








RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES








(Unaudited)








(In thousands)








 





 

 






 






 






 






 






 






 








 





 

Three Months Ended

December 31






 






Twelve Months Ended

December 31








 





 

2025






 






2024






 






2025






 






2024








Reconciliation of Adjusted EBITDA:





 

 






 






 






 






 






 






 








GAAP Net Income (Loss)





 

$






41,149






 






 






$






5,113






 






 






$






66,353






 






 






$






24,138






 








GAAP Net Income (Loss) as a % of Revenue





 

 






29.3






%






 






 






4.3






%






 






 






12.8






%






 






 






5.4






%








Amortization of intangible assets





 

 






3,329






 






 






 






3,609






 






 






 






13,153






 






 






 






14,849






 








Depreciation expense





 

 






1,968






 






 






 






2,643






 






 






 






8,262






 






 






 






8,610






 








Stock-based compensation expense





 

 






10,901






 






 






 






9,629






 






 






 






43,601






 






 






 






36,249






 








Acquisition related expenses (1)





 

 






(12,564






)






 






 






961






 






 






 






(11,971






)






 






 






6,631






 








Other expense (income), net (2)





 

 






(3,546






)






 






 






(1,967






)






 






 






(13,176






)






 






 






(11,647






)








Other adjustments (3)





 

 






1,590






 






 






 






7,807






 






 






 






34,466






 






 






 






11,450






 








Income tax expense (benefit)





 

 






(515






)






 






 






(1,670






)






 






 






1,848






 






 






 






1,606






 








Adjusted EBITDA





 

$






42,312






 






 






$






26,125






 






 






$






142,536






 






 






$






91,886






 








Adjusted EBITDA as a % of Revenue





 

 






30.1






%






 






 






22.0






%






 






 






27.6






%






 






 






20.6






%








 





 

 






 






 






 






 






 






 








Reconciliation of Non-GAAP Net Income (Loss)





 

 






 






 






 






 






 






 








GAAP Net Income (Loss)





 

$






41,149






 






 






$






5,113






 






 






$






66,353






 






 






$






24,138






 








Amortization of intangible assets





 

 






3,329






 






 






 






3,609






 






 






 






13,153






 






 






 






14,849






 








Stock-based compensation expense





 

 






10,901






 






 






 






9,629






 






 






 






43,601






 






 






 






36,249






 








Acquisition related expenses (1)





 

 






(12,564






)






 






 






961






 






 






 






(11,971






)






 






 






6,631






 








Other adjustments (3)





 

 






1,590






 






 






 






7,807






 






 






 






34,466






 






 






 






11,450






 








Tax adjustments (4)





 

 






(1,590






)






 






 






1,830






 






 






 






(2,397






)






 






 






(349






)








Non-GAAP Net Income





 

$






42,815






 






 






$






28,949






 






 






$






143,205






 






 






$






92,968






 








 





 

 






 






 






 






 






 






 








Reconciliation of Non-GAAP Earnings per Share





 

 






 






 






 






 






 






 








Diluted earnings per share, GAAP





 

$






0.51






 






 






$






0.06






 






 






$






0.82






 






 






$






0.31






 








Amortization of intangible assets





 

 






0.04






 






 






 






0.05






 






 






 






0.16






 






 






 






0.19






 








Stock-based compensation expense





 

 






0.13






 






 






 






0.12






 






 






 






0.54






 






 






 






0.46






 








Acquisition related expenses (1)





 

 






(0.15






)






 






 






0.01






 






 






 






(0.15






)






 






 






0.08






 








Other adjustments (3)





 

 






0.02






 






 






 






0.10






 






 






 






0.43






 






 






 






0.15






 








Tax adjustments (4)





 

 






(0.02






)






 






 






0.02






 






 






 






(0.03






)






 






 






—






 








Rounding and impact of dilutive shares





 

 






—






 






 






 






—






 






 






 






0.01






 






 






 






—






 








Diluted earnings per share, non-GAAP





 

$






0.53






 






 






$






0.36






 






 






$






1.78






 






 






$






1.19






 








 





 

 






 






 






 






 






 






 








Weighted average shares outstanding used in computing diluted earnings per share





 

 






 






 






 






 






 






 








Diluted, GAAP





 

 






81,387,089






 






 






 






79,905,412






 






 






 






80,573,140






 






 






 






78,163,217






 








Dilutive effect of equity awards (5)





 

 






—






 






 






 






—






 






 






 






—






 






 






 






—






 








Diluted, non-GAAP





 

 






81,387,089






 






 






 






79,905,412






 






 






 






80,573,140






 






 






 






78,163,217






 









1.






 






Includes transaction-related expenses and post-combination compensation expenses. For the three months ended December 31, 2025, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to NanoString ($0.7 million) and contingent consideration associated with the acquisition of C2i Genomics ($11.9 million). For the three months ended December 31, 2024, adjustments consist primarily of transaction-related expenses associated with the acquisition of C2i Genomics ($1.0 million). For the twelve months ended December 31, 2025, adjustments consist primarily of additional transaction-related expenses associated with the NanoString contingent consideration ($1.0 million) partially offset by expenses associated with the acquisition of C2i Genomics ($1.6 million). For the twelve months ended December 31, 2024, adjustments consist primarily of transaction-related expenses associated with the acquisition of C2i Genomics.








2.






 






Includes interest income and income related to research tax credits.








3.






 






For the three months ended December 31, 2025, adjustments primarily include expenses related to the restructuring and liquidation proceedings of Veracyte SAS ($1.4 million) and other legal proceedings ($0.2 million). For the three months ended December 31, 2024, adjustments primarily include the exclusion of unrealized losses associated with foreign exchange impacts on stock-based compensation and intercompany loans ($1.9 million), expense related to Veracyte SAS site investment review ($3.2 million) and expense related to the impairment charge associated with HalioDx ($2.7 million). For the twelve months ended December 31, 2025, adjustments primarily include additional expense related to Veracyte SAS impairment loss ($20.5 million), Veracyte SAS investment review ($7.7 million), the exclusion of unrealized loss related to Veracyte SAS deconsolidation ($6.7 million), the restructuring and liquidation proceedings of Veracyte SAS ($2.4 million), and other legal proceedings ($0.8 million), partially offset by adjustments related to restructuring costs ($0.1 million), vendor legal settlement ($2.8 million), and the exclusion of unrealized gains associated with foreign exchange impacts on stock-based compensation and intercompany loans ($2.3 million). For the twelve months ended December 31, 2024, adjustments primarily include expense related to restructuring costs associated with a reduction in our Biopharmaceutical and Other segment and with portfolio prioritization, expense related to Veracyte SAS site investment review, expense related to the impairment charge associated with HalioDx and the exclusion of unrealized losses associated with foreign exchange impacts on stock-based compensation and intercompany loans.








4.






 






Incremental non-GAAP tax expense reflects the tax impact of the non-GAAP adjustments listed.








5.






 






In those periods in which GAAP net (loss) income is negative and non-GAAP net (loss) income is positive, non-GAAP diluted weighted average shares outstanding includes potentially dilutive common shares from equity awards as determined using the treasury stock method.







 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260225137453/en/
Investors:

Shayla Gorman

investors@veracyte.com


Media:

Molly Cornbleet

media@veracyte.com


Original: Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results